PT87940B - Processo para a preparacao de dna do virus papillom humano tipo 41 e de proteinas por ele codificadas - Google Patents
Processo para a preparacao de dna do virus papillom humano tipo 41 e de proteinas por ele codificadas Download PDFInfo
- Publication number
- PT87940B PT87940B PT87940A PT8794088A PT87940B PT 87940 B PT87940 B PT 87940B PT 87940 A PT87940 A PT 87940A PT 8794088 A PT8794088 A PT 8794088A PT 87940 B PT87940 B PT 87940B
- Authority
- PT
- Portugal
- Prior art keywords
- hpv
- dna
- papillom
- human
- diagnosis
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 7
- 241000700605 Viruses Species 0.000 title claims description 5
- 208000003154 papilloma Diseases 0.000 title claims description 5
- 238000002360 preparation method Methods 0.000 title description 2
- 238000003745 diagnosis Methods 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 238000001574 biopsy Methods 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 21
- 238000010367 cloning Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 3
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000000260 Warts Diseases 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 201000008261 skin carcinoma Diseases 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000883306 Huso huso Species 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 201000003761 Vaginal carcinoma Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 208000012999 benign epithelial neoplasm Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/708—Specific hybridization probes for papilloma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
DESCRIÇÃO
Os vírus Papillom humanos (HPV) constituem um grupo de cerca de 40 tipos diferentes (vida Hausen,
M. e Schneider, A. (1987), The Papillomaviruses, Howley P.M. e Saizmann, N.P. (editores), no prelo). Os HPV foram descobertos em relação com neoplasmas epiteliais benignos (verrugas, condilomas na região genital) e malignos (carcinoma da pele e da vagina).
Os vírus Papillom não se multiplicam em cultura. A utilização do vírus Papillom humano com DNA do tipo 41 (HPV 41 DNA) como meio do diagnóstico bem como o isolamento dos produtos de expressão, a sua utilização como ant/ genes, o isolamento de anticorpos e a preparação de meios de diagnóstico e de terapêutica deles derivados pressupõe por
- 1 CR.
isso a utilização de técnicas de engenharia genética.
fundamento da invenção é o isolamento, pela primeira vez, do HPV 41, a caracterização parcial do seu genoma, bem como a sua clonagem em pUC19. Por esta via abre-se um caminho para o diagnóstico precoce de tumores cutâneos que estão associados com o HPV 41.
A invenção encontra-se definida nas rei. vindicações da patente. Os outros aspectos da invenção esclarecem-se seguidamente em detalhe.
A clonagem do HPV 41 possibilitou a com paração com outros 40 HPV. Os HPV 7,8,10,17,27,29,30 e 31 estão relativamente relacionados com ele, tendo-se identificado a colinearidade do HPV 41 com o HPV 8 (Fig.2) e estabelecido as cartas genómicas físicas para cisões com enzimas de restrição (Fig.l).
Conseguiu-se deste modo um processo de testar neoplasias, em especial carcinomas da pele, pela presença do HPV 41 e, através de anticorpos para proteínas de HPV 41, de intervir terapêuticamente.
EXEMPLOS
1. Isolamento do DNA epissomai de HPV 41
Recolheram-se biópsias de tecidos de verruga de três regiões diferentes do corpo de uma rapariga de 15 anos e congelaram-se imediatamente e armazenaram-se a -702C . Isolou-se daí DNA de alto peso molecular, como descrito (Gissmann et al. (1982), Int. J. Câncer 29, 143-146).
A partir deste DNA celular, obteve-se DNA de cadeia dupla fechado em anel, segundo Radloff et al. (1967) Proc. Nat. Acad. Sei. 57, 1514-1521, centrifugando-se cerca de 10 pg de DNA numa centrifugadora 50Ti (Beckmann Corp.) a 45 000 Upm, durante 48 horas em CsCl (densidade l,56g/ /ml) na presença de 600 pg/ml de brometo de etldio, e recolhendo-se em seguida as fracções de densidade 1,59-1,60.
Alternativamente, pode identificar-se e isolar-se o DNA
epissomal de HPV 41 do DNA não cortado do mesmo material de biópsia, em geles de agarose corados com brometo de etídio (1% de agarose (Seakem ME) em 40mM Tris-acetato, 2mM EDTA (pH 7,8)).
2. Clonagem de HPV 41 no plasmídeo pUC 19
Como vector de clonagem escolheu-se o conhecido plasmídeo pUC 19 (Yanish-Perron et al. (1985), Gene 33, 133-119) .
Clonou-se em pUC 19 o DNA de cadeia dupla circular fechada, após cisão com BamHI cular Cloning: a Laboratory Laboratory Press, New York) recombinantes pelo teste da al. (1977), Proc. Nat.Acad. analisaram-se os pedaços de rápida do DNA ( Birnboim, H Acids Res. 7, 1513-1523).
(Maniatis et al.(1982), Mole
Manual; Cold Spring Harbor , Identificaram-se os clonos /3-galactosidase (Messing et Sei USA 74, 3642-3646) e DNA ligados, após extraeçao ,L. e Doly (1979), Nucl.
Obtiveram-se dois recombinantes, dos quais um, ο K10, continha uma inserção de 6,6 Kb (quilobases) e o outro, ο K6, uma inserção de 0,98 kb. Identifiouc-se a homolo gia destas sequências clonadas por meio de hibridação com DNA epissomal do material de biópsia.
3. Cartas genómicas físicas do HPV 41
Digeriu-se o DNA de HPV 41, separado do vector por cisão com Bam Hl, com as endonucleases de restrição Accl, BglII,Xbal, Smal, EcoRI, Pstl e HincII e estabeleceram-se as respectivas cartas genómicas físicas, de acordo com métodos gerais conhecidos. O resultado apresenta-se na Fig. 1, servindo as posiçoes de corte Kpnl isola das para linearizar a molécula de HPV 41.
4. Comparação com outros HPV
Comparou-se o DNA do genoma de HPV 41 com os DNA's de 40 tipos de HPV comerciais por meio de hibridação DNA/
/DNA sob várias restrições (E.M. Southern (1975), J. Mol. Biol. 98, 503-517).
Em condições de elevada restrição (temperatura de fusão Tm -20°C) o DNA de HPV 41K 10 hibridiza parcialmente com o DNA de HPV 29. 0 DNA do clono K 6 hibridiza apenas em condições de baixa restrição (Tm -402C) com o DNA de HPV 3 e 13.
A Fig. 2 mostra a colinearidade do HPV 8 com base nos tejs tes de hibridação.
Conhecendo-se a sequência de DNA do HPV 8 ( Fuchs et al. (1986), J. Virol. 58, 626-634) conseguem-se derivar as ordens de leitura abertas do HPV 41 e obter-se desse modo as proteínas de HPV 41 de acordo com métodos gerais conhecidos para a subclonagem dos clonos K 10 e K 6 seguida da expressão em sistemas de expressão procariõticos ou eucarióticos.
Os plasmideos HPV 41, clono K 6 e clono K 10 registaram-se (em E. coli), a 3.7.1987, na Colecção alemã para microorganismos (Deutschen Sammlung fur Mikroorganismen ), sob os números DSM 4174 P (para K 6) e DSM 4175 P (para K 10).
Claims (1)
- REIVINDICAÇÕES-lê.Processo para a expressão do DNA do virus Papillom humano (HPV) 41, caracterizado por se introduzir este DNA, na forma em que existe nos clonos K 10 e K 6, em vectores de expressão adequados e se efectuar a sua expressão em células eucarióticas ou procarióticas.-22.Processo para o diagnóstico de infecções provocadas por HPV 41, caracterizado por se empregarem proteínas HPV 41, quando preparadas de acordo com a reivindicação 1.-3ê.Processo para o diagnóstico de infecções provocadas por HPV 41, caracterizado por se empregar DNA de HPV 41, quando preparado de acordo com a reivindicação 1.-4d.Processo para o diagnóstico com HPV 41, caracterizado por se empregarem anticorpos contra proteínas HPV 41.-5ê.Processo para o diagnóstico de infecções provocadas por HPV 41, caracterizado por se pôr em contacto material de biópsia ou de colheita com um meio de diagnóstico, quando preparado de acordo com as reivindicações 2, 3 ou 4.A requerente declara que o primeiro pedido desta patente foi apresentado na República Federal Alemã em 11 de Julho de 1987, sob ο ηθ. P 37 22 968.0.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19873722968 DE3722968A1 (de) | 1987-07-11 | 1987-07-11 | Humaner papillomvirus typ 41, seine dna und die dafuer kodierenden proteine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PT87940A PT87940A (pt) | 1989-06-30 |
| PT87940B true PT87940B (pt) | 1995-03-01 |
Family
ID=6331386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT87940A PT87940B (pt) | 1987-07-11 | 1988-07-08 | Processo para a preparacao de dna do virus papillom humano tipo 41 e de proteinas por ele codificadas |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US5142032A (pt) |
| EP (1) | EP0301289B1 (pt) |
| JP (1) | JP2746380B2 (pt) |
| KR (1) | KR970005047B1 (pt) |
| AT (1) | ATE111158T1 (pt) |
| AU (1) | AU617330B2 (pt) |
| CA (1) | CA1340322C (pt) |
| DE (2) | DE3722968A1 (pt) |
| DK (1) | DK173259B1 (pt) |
| ES (1) | ES2060625T3 (pt) |
| FI (1) | FI100538B (pt) |
| PT (1) | PT87940B (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1486211B1 (en) | 1993-04-30 | 2008-10-22 | Wellstat Biologics Corporation | Compositions for treating cancer using viruses |
| DE19526386C1 (de) * | 1995-07-19 | 1997-01-02 | Deutsches Krebsforsch | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen |
| CA2365901A1 (en) * | 1999-04-14 | 2000-10-19 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| US20030059806A1 (en) * | 2001-01-05 | 2003-03-27 | Science & Technology Corporation @ Unm | Probes for the detection of human papillomavirus |
| US7704965B2 (en) * | 2002-06-26 | 2010-04-27 | The Penn State Research Foundation | Methods and materials for treating human papillomavirus infections |
| EP2576840B1 (en) | 2010-05-25 | 2018-10-17 | QIAGEN Gaithersburg, Inc. | Fast results hybrid capture assay and associated strategically-truncated probes |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2648303B2 (ja) * | 1985-04-04 | 1997-08-27 | ジョージタウン・ユニバーシティ | 型特異的乳頭腫ウイルスｄｎａ配列およびペプチド |
| DE3625257A1 (de) * | 1986-07-23 | 1988-02-04 | Behringwerke Ag | Expressionsprodukte der menschlichen papillomviren typ 16 und 18, fuer diese proteine spezifische antikoerper und diese antikoerper bzw. entsprechende dna enthaltende diagnostika |
| US4849331A (en) * | 1987-06-09 | 1989-07-18 | Life Technologies, Inc. | Human papillomavirus 44 nucleic acid hybridization probes and methods for employing the same |
| US4849334A (en) * | 1987-06-09 | 1989-07-18 | Life Technologies, Inc. | Human papillomavirus 43 nucleic acid hybridization probes and methods for employing the same |
| DE3722967A1 (de) * | 1987-07-11 | 1989-01-19 | Behringwerke Ag | Monoklonale antikoerper gegen e7-protein des humanen papillomvirus typ 16, verfahren zu ihrer herstellung sowie ihre verwendung |
| DE3826793A1 (de) * | 1988-08-06 | 1990-03-08 | Behringwerke Ag | Humaner papillomvirus typ 57, seine dna und die davon kodierten proteine |
-
1987
- 1987-07-11 DE DE19873722968 patent/DE3722968A1/de not_active Withdrawn
-
1988
- 1988-07-07 FI FI883255A patent/FI100538B/fi not_active IP Right Cessation
- 1988-07-07 AT AT88110851T patent/ATE111158T1/de not_active IP Right Cessation
- 1988-07-07 DE DE3851391T patent/DE3851391D1/de not_active Expired - Fee Related
- 1988-07-07 ES ES88110851T patent/ES2060625T3/es not_active Expired - Lifetime
- 1988-07-07 EP EP88110851A patent/EP0301289B1/de not_active Expired - Lifetime
- 1988-07-08 PT PT87940A patent/PT87940B/pt not_active IP Right Cessation
- 1988-07-08 DK DK198803834A patent/DK173259B1/da not_active IP Right Cessation
- 1988-07-08 CA CA000571554A patent/CA1340322C/en not_active Expired - Fee Related
- 1988-07-08 AU AU18878/88A patent/AU617330B2/en not_active Ceased
- 1988-07-08 US US07/216,913 patent/US5142032A/en not_active Expired - Lifetime
- 1988-07-11 JP JP63172512A patent/JP2746380B2/ja not_active Expired - Fee Related
- 1988-07-11 KR KR1019880008579A patent/KR970005047B1/ko not_active IP Right Cessation
-
1993
- 1993-11-23 US US08/156,936 patent/US5382509A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU617330B2 (en) | 1991-11-28 |
| PT87940A (pt) | 1989-06-30 |
| DK173259B1 (da) | 2000-05-29 |
| DK383488D0 (da) | 1988-07-08 |
| FI883255A0 (fi) | 1988-07-07 |
| JP2746380B2 (ja) | 1998-05-06 |
| US5382509A (en) | 1995-01-17 |
| EP0301289B1 (de) | 1994-09-07 |
| EP0301289A1 (de) | 1989-02-01 |
| CA1340322C (en) | 1999-01-19 |
| JPS6455182A (en) | 1989-03-02 |
| AU1887888A (en) | 1989-04-20 |
| DE3722968A1 (de) | 1989-01-19 |
| KR890002402A (ko) | 1989-04-10 |
| ES2060625T3 (es) | 1994-12-01 |
| KR970005047B1 (ko) | 1997-04-11 |
| ATE111158T1 (de) | 1994-09-15 |
| DK383488A (da) | 1989-01-12 |
| DE3851391D1 (de) | 1994-10-13 |
| FI883255A (fi) | 1989-01-12 |
| FI100538B (fi) | 1997-12-31 |
| US5142032A (en) | 1992-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shirasawa et al. | Transcriptional differences of the human papillomavirus type 16 genome between precancerous lesions and invasive carcinomas | |
| EP0243221B1 (en) | Determined dna sequences derived from a papillomavirus genome, their uses for in vitro diagnostic purposes and the production of antigenic compositions | |
| Raab-Traub et al. | Epstein-Barr virus transcription in nasopharyngeal carcinoma | |
| Ostrow et al. | Human papillomavirus DNA in cutaneous primary and metastasized squamous cell carcinomas from patients with epidermodysplasia verruciformis. | |
| JP3207389B2 (ja) | 乳頭腫ウィルス及びその診断方法 | |
| JPS61216700A (ja) | 乳頭腫ウイルスに対するプローブ及び乳頭腫ウイルス感染の検出法 | |
| Grimmel et al. | Characterization of a new human papillomavirus (HPV 41) from disseminated warts and detection of its DNA in some skin carcinomas | |
| JPH06504672A (ja) | 乳頭腫ウイルスｈｐｖ３９のゲノムから誘導されるｄｎａ配列、ｉｎ ｖｉｔｒｏ診断及び免疫原組成物の生成への前記配列の応用 | |
| Das et al. | Human papillomavirus DNA sequences in adenocarcinoma of the uterine cervix in Indian women | |
| PT87940B (pt) | Processo para a preparacao de dna do virus papillom humano tipo 41 e de proteinas por ele codificadas | |
| SAITO et al. | New human papillomavirus sequences in female genital tumors from Japanese patients | |
| US6395512B1 (en) | DNA coding for a peptide of a papilloma virus main capside protein and use thereof | |
| US6127164A (en) | Human papilloma virus type 57, diagnosis of HPV 57 infections and method therefor | |
| O'Banion et al. | Cloning and characterization of a papillomavirus associated with papillomas and carcinomas in the European harvest mouse (Micromys minutus) | |
| Ishibashi et al. | Presence of human papillomavirus type-6-related sequences in inverted nasal papillomas | |
| ADACHI et al. | A novel type of human papilloma virus DNA from the lesion of epidermodysplasia verruciformis | |
| Suzuki et al. | Nucleotide and amino acid sequence variations in the L1 open reading frame of human papillomavirus type 6 | |
| JPH0279980A (ja) | ヒトパピローマウイルス５２ｂ遺伝子 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG3A | Patent granted, date of granting |
Effective date: 19940818 |
|
| PC3A | Transfer or assignment |
Free format text: 19981125 BEHRING DIAGNOSTICS GMBH DE |
|
| PD3A | Change of proprietorship |
Owner name: DADE BEHRING MARBURG GMBH Effective date: 19981125 |
|
| MM4A | Annulment/lapse due to non-payment of fees, searched and examined patent |
Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20070219 |